Cytostatic drugs, neuregulin activation of erbb receptors, and angiogenesis

Current Hypertension Reports

Volumn 12, Issue 6, 2010, Pages 411-417

  Hedhli, Nadia ^a   Russell, Kerry Strong ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Angiogenesis; Cardiotoxicity; Endothelial cells; erbB receptors; Myocyte; Neuregulin; Trastuzumab

Indexed keywords

CYTOSTATIC AGENT; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; NEU DIFFERENTIATION FACTOR; PLACEBO; TAMOXIFEN; TRASTUZUMAB;

ANGIOGENESIS; CANCER INHIBITION; CARDIOMYOPATHY; CLINICAL TRIAL; DRUG TARGETING; HEART DISEASE; HEART FAILURE; HEART FUNCTION; HEART MUSCLE CELL; HEART PROTECTION; HUMAN; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PROTEIN FUNCTION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS INHIBITION; REVIEW; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIUM;

ANIMALS; ANTIBODIES, MONOCLONAL; CARDIOVASCULAR DISEASES; CELL PROLIFERATION; CYTOSTATIC AGENTS; DRUG EVALUATION, PRECLINICAL; ENDOTHELIAL CELLS; HUMANS; MYOCYTES, CARDIAC; NEOVASCULARIZATION, PHYSIOLOGIC; NEUREGULIN-1; RATS; RECEPTOR, ERBB-2; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION;

EID: 78649919273     PISSN: 15226417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11906-010-0148-9     Document Type: Review

References (50)

1. MH Chen 2009 Cardiac dysfunction induced by novel targeted anticancer therapy: an emerging issue Curr Cardiol Rep 11 167 174 1:CAS:528: DC%2BD1MXhsVClsr7P 10.1007/s11886-009-0025-9 19379636 This is a nice broad review of the cardiotoxicity of newer chemotherapeutic drugs
2. DL Falls 2003 Neuregulins: functions, forms, and signaling strategies Exp Cell Res 284 14 30 1:CAS:528:DC%2BD3sXitVyltr8%3D 10.1016/S0014-4827(02)00102-7 12648463 (Pubitemid 36335807)
3. D Meyer T Yamaai A Garratt, et al. 1997 Isoform-specific expression and function of neuregulin Development 124 3575 3586 1:CAS:528:DyaK2sXmvVWgsb4%3D 9342050
4. X Liu X Gu Z Li, et al. 2006 Neuregulin-1/erbB-activation improves cardiac function and survival in models of ischemic, dilated, and viral cardiomyopathy J Am Coll Cardiol 48 1438 1447 1:CAS:528:DC%2BD28XhtVagtb7I 10.1016/j.jacc.2006.05.057 17010808 (Pubitemid 44436803)
5. R Gao J Zhang L Cheng, et al. 2010 A phase II, randomized, double-blind, multicenter, based on standard therapy, placebo-controlled study of the efficacy and safety of recombinant human neuregulin-1 in patients with chronic heart failure J Am Coll Cardiol 55 1907 1914 1:CAS:528:DC%2BC3cXns1GisLY%3D 10.1016/j.jacc.2009.12.044 20430261 This is the first published clinical trial of neuregulin in patients with heart failure
6. TP Garrett NM McKern M Lou, et al. 2003 The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors Mol Cell 11 495 505 1:CAS:528:DC%2BD3sXit1WgsLo%3D 10.1016/S1097-2765(03)00048-0 12620236 (Pubitemid 36293841)
7. K Lee H Simon H Chen, et al. 1995 Requirement for neuregulin receptor erbB2 in neural and cardiac development Nature 378 394 398 1:CAS:528: DyaK2MXps1ams7g%3D 10.1038/378394a0 7477377
8. D Riese T van Raaij G Plowman, et al. 1995 The cellular response to neuregulins is governed by complex interactions of the erbB receptor family Mol Cell Biol 15 5770 5776 1:CAS:528:DyaK2MXotlamsr8%3D 7565730
9. YY Zhao DR Sawyer RR Baliga, et al. 1998 Neuregulins promote survival and growth of cardiac myocytes. Persistence of ErbB2 and ErbB4 expression in neonatal and adult ventricular myocytes J Biol Chem 273 10261 10269 1:CAS:528:DyaK1cXivFKntro%3D 10.1074/jbc.273.17.10261 9553078 (Pubitemid 28227629)
10. S Rohrbach B Niemann RE Silber J Holtz 2005 Neuregulin receptors erbB2 and erbB4 in failing human myocardium-depressed expression and attenuated activation Basic Res Cardiol 100 240 249 1:CAS:528:DC%2BD2MXkslKls7s%3D 10.1007/s00395-005-0514-4 15685397 (Pubitemid 41348815)
11. KS Russell DF Stern PJ Polverini JR Bender 1999 Neuregulin activation of ErbB receptors in vascular endothelium leads to angiogenesis Am J Physiol 277 H2205 H2211 1:CAS:528:DC%2BD3cXpsF2n 10600838
12. GM Cote TA Miller NK Lebrasseur, et al. 2005 Neuregulin-1alpha and beta isoform expression in cardiac microvascular endothelial cells and function in cardiac myocytes in vitro Exp Cell Res 311 135 146 1:CAS:528:DC%2BD2MXhtFKmtb3M 10.1016/j.yexcr.2005.08.017 16185687 (Pubitemid 41527182)
13. A Kalinowski NJ Plowes Q Huang, et al. 2010 Metalloproteinase-dependent cleavage of neuregulin and autocrine stimulation of vascular endothelial cells FASEB J 24 2567 2575 1:CAS:528:DC%2BC3cXptV2ku7k%3D 10.1096/fj.08-129072 20215529 The inflammatory cytokines IL-6 and IFNγ induce metalloproteinase-dependent cleavage of neuregulin from endothelial cells
14. IP Uray JH Connelly V Thomazy, et al. 2002 Left ventricular unloading alters receptor tyrosine kinase expression in the failing human heart J Heart Lung Transplant 21 771 782 10.1016/S1053-2498(02)00390-X 12100903 (Pubitemid 34718182)
15. B Ky SE Kimmel RN Safa, et al. 2009 Neuregulin-1 beta is associated with disease severity and adverse outcomes in chronic heart failure Circulation 120 310 317 1:CAS:528:DC%2BD1MXos1ent7c%3D 10.1161/CIRCULATIONAHA.109.856310 19597049 Increased NRG-1β in human serum is associated with heart failure, death, and cardiac transplantation, suggesting that NRG may be an important clinical biomarker
16. M Hintsanen M Elovainio S Puttonen, et al. 2007 Neuregulin-1 genotype moderates the association between job strain and early atherosclerosis in young men Ann Behav Med 33 148 155 10.1007/BF02879896 17447867 (Pubitemid 47289493)
17. CM Clement LK Thomas Y Mou, et al. 2007 Neuregulin-1 attenuates neointimal formation following vascular injury and inhibits the proliferation of vascular smooth muscle cells J Vasc Res 44 303 312 1:CAS:528: DC%2BD2sXms1yrtro%3D 10.1159/000101776 17438359 (Pubitemid 46956833)
18. G Xu T Watanabe Y Iso, et al. 2009 Preventive effects of heregulin-β1 on macrophage foam cell formation and atherosclerosis Circ Res 105 500 510 1:CAS:528:DC%2BD1MXhtVekt7%2FJ 10.1161/CIRCRESAHA.109.193870 19644050 NRG-1 inhibits atherogenesis and macrophage foam-cell formation via scavenger receptor class A (SR-A), acyl-coenzyme A:cholesterol acyltransferase (ACAT)1, and ATP-binding cassette transporter ABCA1
19. DJ Slamon B Leyland-Jones S Shak, et al. 2001 Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 344 783 792 1:CAS:528:DC%2BD3MXisVGktrc%3D 10.1056/NEJM200103153441101 11248153 (Pubitemid 32222155)
20. RR Baliga DR Pimental YY Zhao, et al. 1999 NRG-1-induced cardiomyocyte hypertrophy. Role of PI-3-kinase, p70(S6K), and MEK-MAPK-RSK Am J Physiol 277 H2026 H2037 1:CAS:528:DyaK1MXns1yrtrc%3D 10564160
21. K Lemmens P Fransen SU Sys, et al. 2004 Neuregulin-1 induces a negative inotropic effect in cardiac muscle: role of nitric oxide synthase Circulation 109 324 326 1:CAS:528:DC%2BD2cXks1Citw%3D%3D 10.1161/01.CIR.0000114521.88547.5E 14732742 (Pubitemid 38133898)
22. R Fukazawa TA Miller Y Kuramochi, et al. 2003 Neuregulin-1 protects ventricular myocytes from anthracycline-induced apoptosis via erbB4-dependent activation of PI3-kinase/Akt J Mol Cell Cardiol 35 1473 1479 1:CAS:528:DC%2BD3sXpsVSntr0%3D 10.1016/j.yjmcc.2003.09.012 14654373 (Pubitemid 37491190)
23. Y Nakaoka K Nishida M Narimatsu, et al. 2007 Gab family proteins are essential for postnatal maintenance of cardiac function via neuregulin-1/ErbB signaling J Clin Invest 117 1771 1781 1:CAS:528:DC%2BD2sXnvVagtbY%3D 10.1172/JCI30651 17571162 (Pubitemid 47036311)
24. T Horie K Ono H Nishi, et al. 2010 Acute doxorubicin cardiotoxicity is associated with miR-146a-induced inhibition of the neuregulin-ErbB pathway Cardiovasc Res 87 656 664 1:CAS:528:DC%2BC3cXhtVansbzO 10.1093/cvr/cvq148 20495188 A novel pathway of erbB4 downregulation may help to explain the synergistic cardiotoxicity between anthracyclines and trastuzumab
25. K Bersell S Arab B Haring B Kuhn 2009 Neuregulin1/erbB4 signaling induces cardiomyocyte proliferation and repair of heart injury Cell 138 257 270 1:CAS:528:DC%2BD1MXhtVSgtrzF 10.1016/j.cell.2009.04.060 19632177 This was the first study to demonstrate that adult cardiac myocytes can proliferate in response to NRG
26. Y Kuramochi GM Cote X Guo, et al. 2004 Cardiac endothelial cells regulate reactive oxygen species-induced cardiomyocyte apoptosis through neuregulin-1beta/erbB4 signaling J Biol Chem 279 51141 51147 1:CAS:528:DC%2BD2cXhtVaqsrvN 10.1074/jbc.M408662200 15385548 (Pubitemid 40017856)
27. Q Huang A Kalinowski M Palmeri, et al. 2005 Neuregulin decreases cardiac myocyte apoptosis induced by hypoxic injury [abstract] Circulation 112 Suppl II II-183
28. F Timolati D Ott L Pentassuglia, et al. 2006 Neuregulin-1 beta attenuates doxorubicin-induced alterations of excitation-contraction coupling and reduces oxidative stress in adult rat cardiomyocytes J Mol Cell Cardiol 41 845 854 1:CAS:528:DC%2BD28XhtFenurrE 10.1016/j.yjmcc.2006.08.002 17005195 (Pubitemid 44635571)
29. L Pentassuglia M Graf H Lane, et al. 2009 Inhibition of erbB2 by receptor tyrosine kinase inhibitors causes myofibrillar structural damage without cell death in adult rat cardiomyocytes Exp Cell Res 315 1302 1312 1:CAS:528:DC%2BD1MXktF2ktrk%3D 10.1016/j.yexcr.2009.02.001 19331811 Inhibition of erbB2 in cardiac myocytes results in an inhibition of excitation contraction coupling and myofibrillar structural damage
30. LP Grazette W Boecker T Matsui, et al. 2004 Inhibition of ErbB2 causes mitochondrial dysfunction in cardiomyocytes: implications for Herceptin-induced cardiomyopathy J Am Coll Cardiol 44 2231 2238 1:CAS:528:DC%2BD2cXhtVCktLrF 10.1016/j.jacc.2004.08.066 15582322 (Pubitemid 39576044)
31. Y Kuramochi X Guo DB Sawyer 2006 Neuregulin activates erbB2-dependent src/FAK signaling and cytoskeletal remodeling in isolated adult rat cardiac myocytes J Mol Cell Cardiol 41 228 235 1:CAS:528:DC%2BD28XntlGhs74%3D 10.1016/j.yjmcc.2006.04.007 16769082 (Pubitemid 44080212)
32. JW Schneider AY Chang A Garratt 2002 Trastuzumab cardiotoxicity: speculations regarding pathophysiology and targets for further study Semin Oncol 29 22 28 1:CAS:528:DC%2BD38XmsFWnsbk%3D 12138394
33. TM Suter M Procter DJ van Veldhuisen, et al. 2007 Trastuzumab-associated cardiac adverse effects in the Herceptin adjuvant trial J Clin Oncol 25 3859 3865 1:CAS:528:DC%2BD2sXhtFanu7zE 10.1200/JCO.2006.09.1611 17646669 (Pubitemid 47477261)
34. DL Brutsaert 2003 Cardiac endothelial-myocardial signaling: its role in cardiac growth, contractile performance, and rhythmicity Physiol Rev 83 59 115 1:CAS:528:DC%2BD3sXntlGgsw%3D%3D 12506127
35. K Li JL Rouleau LJ Andries DL Brutsaert 1993 Effect of dysfunctional vascular endothelium on myocardial performance in isolated papillary muscles Circ Res 72 768 777 1:STN:280:DyaK3s7osFWktQ%3D%3D 8443868
36. K Rakusan PW Hrdina Z Turek, et al. 1984 Cell size and capillary supply of the hypertensive rat heart: quantitative study Basic Res Cardiol 79 389 395 1:STN:280:DyaL2M%2Fit1eltw%3D%3D 10.1007/BF01908138 6237640
37. O Hudlicka M Brown S Egginton 1992 Angiogenesis in skeletal and cardiac muscle Physiol Rev 72 369 417 1:CAS:528:DyaK38XisFaltbY%3D 1372998
38. K Walsh I Shiojima 2007 Cardiac growth and angiogenesis coordinated by intertissue interactions J Clin Invest 117 3176 3179 1:CAS:528: DC%2BD2sXht12isr%2FM 10.1172/JCI34126 17975662 (Pubitemid 350096973)
39. D Tirziu E Chorianopoulos KL Moodie, et al. 2007 Myocardial hypertrophy in the absence of external stimuli is induced by angiogenesis in mice J Clin Invest 117 3188 3197 1:CAS:528:DC%2BD2sXht12isrzM 10.1172/JCI32024 17975666 (Pubitemid 350096977)
40. I Shiojima K Sato Y Izumiya, et al. 2005 Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure J Clin Invest 115 2108 2118 1:CAS:528:DC%2BD2MXntFCmtLs%3D 10.1172/JCI24682 16075055 (Pubitemid 41134152)
41. MR Hoenig C Bianchi A Rosenzweig FW Sellke 2008 The cardiac microvasculature in hypertension, cardiac hypertrophy, and diastolic heart failure Curr Vasc Pharmacol 6 292 300 1:CAS:528:DC%2BD1cXhtFKms7rO 10.2174/157016108785909779 18855717 This is a review of the importance of determining mechanisms to activate angiogenic genes in cardiac-related myopathies that are associated with capillary rarefaction
42. MR Hoenig C Bianchi A Rosenzweig FW Sellke 2008 Decreased vascular repair and neovascularization with ageing: mechanisms and clinical relevance with an emphasis on hypoxia-inducible factor-1 Curr Mol Med 8 754 767 1:CAS:528:DC%2BD1MXhsleqtLY%3D 10.2174/156652408786733685 19075673 Loss of vascular repair in aging animals is associated with decreased hypoxia-inducible factor signaling and VEGF activation
43. JL Houghton MJ Frank AA Carr, et al. 1990 Relations among impaired coronary flow reserve, left ventricular hypertrophy and thallium perfusion defects in hypertensive patients without obstructive coronary artery disease J Am Coll Cardiol 15 43 51 1:STN:280:DyaK3c7htVOmsg%3D%3D 10.1016/0735-1097(90) 90173-M 2136877
44. K Debl B Djavidani S Buchner, et al. 2006 Delayed hyperenhancement in magnetic resonance imaging of left ventricular hypertrophy caused by aortic stenosis and hypertrophic cardiomyopathy: visualisation of focal fibrosis Heart 92 1447 1451 1:STN:280:DC%2BD28rkvVWhuw%3D%3D 10.1136/hrt.2005.079392 16606864 (Pubitemid 44578839)
45. N Hedhli A Kalinowski Q Huang, et al. 2009 Endothelial neuregulin expression is essential for maintaining capillaries in the heart and preserving cardiac function [abstract 3340] Circulation 120 S791
46. R Bagheri-Yarmand RK Vadlamudi RA Wang, et al. 2000 Vascular endothelial growth factor up-regulation via p21-activated kinase-1 signaling regulates heregulin-beta1-mediated angiogenesis J Biol Chem 275 39451 39457 1:CAS:528:DC%2BD3cXptFSrtrs%3D 10.1074/jbc.M006150200 10967114 (Pubitemid 32058970)
47. E Iivanainen I Paatero SM Heikkinen, et al. 2007 Intra- and extracellular signaling by endothelial neuregulin-1 Exp Cell Res 313 2896 2909 1:CAS:528:DC%2BD2sXosFyqtrg%3D 10.1016/j.yexcr.2007.03.042 17499242 (Pubitemid 47126431)
48. D Panutsopulos DL Arvanitis C Tsatsanis, et al. 2005 Expression of heregulin in human coronary atherosclerotic lesions J Vasc Res 42 463 474 1:CAS:528:DC%2BD2MXhtFWmurnI 10.1159/000088100 16155362 (Pubitemid 41527601)
49. M Guler T Yilmaz I Ozercan T Elkiran 2009 The inhibitory effects of trastuzumab on corneal neovascularization Am J Ophthalmol 147 703 708 10.1016/j.ajo.2008.09.022 19054498 Systemic administration of an erbB2 monoclonal antibody, trastuzumab, can decrease vascular formation
50. N Hedhli LW Dobrucki A Kalinowski, et al. 2009 Endothelial neuregulin expression is essential for angiogenesis in response to hindlimb ischemia [abstract 5111] Circulation 120 S1052